Ryan White Care Hepatitis C & B Language
NATAP Webinars
Heart Health in HIV: Promoting Health and Preventing Disease
Fri, May 16, 2025 12:30 PM EDT
Click here to Register
View all archived NATAP webinars here
Current HIV Articles and News Updates
HIV
EASL:
Identifying Risk Factors Associated with MASH for People Living with HIV
- (05/12/25)
More HIV Articles...
Hepatitis D
HEPATITIS D INFECTION: who should be screened AASLD 2018 HBV Guidelines
EASL:
Virological Response and Safety of Combination Treatment with Bulevirtide and Pegylated Interferon in Chronic Hepatitis D Patients with Advanced Fibrosis/Cirrhosis: 48 Weeks Interim Results from SEE-D Trial
- (05/14/25)
EASL:
Healthcare resource utilisation and costs associated with hepatitis delta virus infection compared with hepatitis B virus monoinfection prior to death among adults in Spain
- (05/14/25)
EASL:
Patient Characteristics and Treatment Patterns Amongst Hepatitis Delta Patients: Results From a Real-World Survey in Europe
- (05/14/25)
EASL:
Pharmacokinetics, Pharmacodynamics, and Safety of Bulevirtide 10 mg Once Daily for 6 Days in Participants With Severe Renal Impairment and in Matched Control Participants With Normal Renal Function
- (05/14/25)
EASL:
Patient Characteristics and Treatment Patterns Amongst Hepatitis Delta Patients: Results From a Real-World Survey in Europe
- (05/14/25)
EASL:
Patient-Reported Outcomes Measuring an Individual's Overall Self-Rated Health After Long-Term Treatment With Bulevirtide 2 mg for Chronic Hepatitis Delta in the Phase 3 MYR301 Trial
- (05/13/25)
More Hep D Articles...
Aging & Perinatally Acquired HIV
CROI:
Thwarting a protein in the hope of a better quality of life: fostemsavir gp120 aging study
- (04/07/25)
CROI:
Plasma Inflammation is Associated With Brain Cellularity in Diffusion-Based Spectral Imaging in HIV
- (03/24/25)
More Aging & HIV Articles...
PrEP
CROI:
The Influence of Racialized Economic Segregation on Unmet HIV prevention Needs in the Real World
- (03/29/25)
More PreP Articles...
Current Hepatitis C and B Articles
Hepatitis C
EASL:
8 weeks of Glecaprevir/Pibrentasvir is highly effective in patients with genotype 3 hepatitis C related cirrhosis, irrespective of the presence of clinically significant portal hypertension
- (05/12/25)
EASL:
Leave no one behind: an examination of how the hepatitis C elimination programme in England is reducing healthcare inequalities
- (05/12/25)
EASL:
Direct measurement of incidence and prevalence of Hepatitis C infection using the gold-standard of prospective HCV re-testing of people at risk. A national needs assessment of people who inject drugs and of all people who use addiction services in England
- (05/12/25)
EASL:
Trends in the effect of direct acting antivirals on mortality in people diagnosed with hepatitis C in England using routine surveillance data
- (05/12/25)
EASL:
Complex multiple morbidity and social vulnerability among hep C patients with delays accessing care UK
- (05/12/25)
EASL:
Mortality benefits of a national program of supported, active care in the treatment of marginalised people with chronic HCV infection
- (05/12/25)
EASL:
Longterm clinical outcomes outcome in Chronic hepatitis C after direct acting antivirals : a Prospective study
- (05/12/25)
EASL:
Outcome in patients with liver cirrhosis and hepatocellular carcinoma : comparing MRI and ultrasound for HCC surveillance
- (05/12/25)
More Hep C Articles...
Hepatitis B
HBV Patient Declaration of Rights
-
EASL:
Outcomes beyond 10 years in entecavir or tenofovir treated Caucasian chronic hepatitis B patients of the real-life PAGE-B cohort
- (05/12/25)
EASL:
Outcomes of 48 Weeks of Therapy and Subsequent 24-Week Post-Treatment Period With Tobevibart (VIR-3434) and Elebsiran (VIR-2218) With or Without Pegylated Interferon Alfa-2a in Chronic Hepatitis B Virus Infection: Findings From the MARCH Study
- (05/12/25)
More Hep B Articles...
Fatty Liver, NAFLD, NASH
EASL:
Treatment with resmetirom for up to two years led to improvement in liver stiffness, fibrosis biomarkers, fibrosis scores and portal hypertension in 122 patients with compensated MASH cirrhosis
- (05/14/25)
EASL:
Use of non-invasive tests to diagnose and follow MASH with liver fibrosis patients treated with resmetirom
- (05/14/25)
More Fatty Liver Articles...
Check Out Our Special NATAP Features
List not necessarily listed here in order of date being held.
https://academicmedicaleducation.com/meeting/2nd-african-workshop-women-hiv-2025
https://academicmedicaleducation.com/meeting/2nd-menopause-hiv-webinar-2025
https://www.croiconference.org
https://academicmedicaleducation.com/meeting/15th-international-workshop-women-hiv-2025
https://acthiv.org/
https://ddw.org/
https://www.easlcongress.eu/
https://asm.org/Events/ASM-Microbe/Home
IAS 2025, the 13th IAS Conference on HIV Science,
Kigali, Rwanda, July 13 to 17,
pre-conferences on 13 July.
https://www.iasociety.org/conferences/ias2025
https://academicmedicaleducation.com/meeting/26th-international-workshop-clinical-pharmacology-hiv-hepatitis-and-other-antiviral-drugs
https://academicmedicaleducation.com/meeting/11th-international-viral-hepatitis-elimination-meeting-ivhem-2025
https://academicmedicaleducation.com/meeting/8th-conference-liver-disease-africa-colda-2025
https://www.eacsociety.org/european-aids-conference/european-aids-conference/
https://idweek.org/
https://academicmedicaleducation.com/meeting/16th-international-workshop-hiv-aging-2025
https://www.aasld.org/the-liver-meeting
https://neurohiv.com/
